Biotech Trials, Visas, and AI
Kilder
- Endpoints: Roivant's autoimmune drug succeeds in two pivotal trials, setting up 2027 filing
- Endpoints: China biotech RiboX reveals first data of circular RNA therapies in people
- BioSpace: As H-1B visa changes keep coming, biopharmas adjust hiring approach
- Endpoints: Rezera files for IPO to back NLRP3 work in peripheral artery disease
- Endpoints: 5 takeaways from Endpoints' AI Day: Agents, AI slop, biosecurity
- STAT: STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved
- STAT: GSK picks up hep B drug approval - STAT
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.